Titration of small molecules in DMSO is a ubiquitous part of the drug discovery workflow. Traditional methods require serial dilution which can be wasteful in terms of tips, intermediate plates and compounds. This process is also time consuming, and reproducibility from researcher to researcher can be a challenge. Traditionally, laboratories have had to accept the potential for carry-over and accumulated pipetting errors, as well as the high labor costs associated with this task. In addition, many laboratories are not performing scientifically optimal titrations, due to equipment or time restrictions. For example, in vitro drug-drug interaction experiments are often desired, but are too complicated to perform routinely.
Low- and medium-throughput laboratories, such as therapeutic or lead optimization departments, cannot always justify the purchase of large automation equipment. Not only can the cost of these systems be prohibitive, they can also impose undesirable limits on assay set-up, and often require specialist knowledge to maintain and program. These laboratories need an affordable solution that meets their demands for flexibility, speed and reliability.
>Join our webinar as we examine the potential for change in dose-response curve set-up for small molecules in DMSO, leading to time savings and dose and plate layout flexibility for drug discovery biologists.
Richard has spent over a decade working in cancer drug discovery and has broad experience ranging from target identification, to assay development and HTS, SPR-based protein-drug interaction analysis, and drug target validation. He currently works in the Medicinal Chemistry Group at the OICR, a translational research institute. Richard runs in vitro assays in support of SAR programs, and has embarked upon a targeted screening program in patient-derived primary cancer cells. In this study drug sensitivity is being combined with RNAi and deep sequencing to identify promising anti-cancer targets.
Dr. Ingo Montenbruck is managing the European Sales Development team at Tecan with focus on “new partnered products” for the drug discovery market. Before joining Tecan, he has worked for Ingenium Pharmaceuticals as Director Business Development with focus on partnering of drug target discovery/validation technologies, and a small molecule-based kinase inhibitor research program. Prior he has worked as Business Manager at Biogen, Germany in the business unit dermatology. He received his Ph.D. in biology from the University of Tuebingen, Germany with focus on microbial genetics.
With more than 10 years of experience in the life science industry, Jessica is the Product Manager for the HP D300 at Tecan Switzerland. Before, she worked in both sales and application support for liquid handling platforms in Tecan US. Prior, she held positions within Biotech Research, focusing on assay development using cell based assays.